StockData

GeoVax Labs vs 60 Degrees Pharmaceuticals

GOVX and SXTP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GOVX and SXTP compare

GeoVax Labs is the larger company, worth 7.9 times as much as 60 Degrees Pharmaceuticals ($14.8M against $1.9M).

60 Degrees Pharmaceuticals grew revenue faster over the last twelve months (73.2% versus −100% for GeoVax Labs).

60 Degrees Pharmaceuticals scores higher on the StockData Score (8 against 6 for GeoVax Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGOVXSXTP
Size and price
Market cap$14.8M$1.9M
Share price$2.01$0.534
Change, 1 year−99.3%−85.3%
Change, 5 years−100.0%–
Beta (5Y)–1.92
Employees193
StockData Score
Total score68 (better)
Valuation score03 (better)
Growth score12 (better)
Performance score01 (better)
Health score5 (better)2
Dividend score00
Valuation
P/S–1.7×
P/B8.4×0.7× (better)
FCF yield−124% (better)−474%
Fair value–$1.34
Margin of safety–60.2%
Growth
Revenue growth (TTM)−100%73.2% (better)
Revenue growth, 5Y average6.4%–
Profitability
Gross margin–19.4%
Operating margin–−775%
Net margin–−730%
FCF margin–−801%
Return on equity−892%−322% (better)
Return on invested capital–−659%
Financial health
Debt / equity0.000.00 (better)
Interest coverage–−1134.8×
Current ratio1.542.32 (better)
Altman Z-score−59.53−22.22 (better)
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions6.7%21.5%
Held by insiders2.7%21.0%
Insider net buying, 12 months$0$30.1K (better)
Short interest, % of float2.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.